Parse Biosciences and Codebreaker Labs announced a collaboration to combine Parse’s single‑cell transcriptomics platform with Codebreaker’s engineered variant libraries to experimentally assess how genetic variants alter single‑cell transcriptomes. The alliance aims to generate datasets that improve whole‑genome interpretation, target discovery, and precision trial design. The partnership leverages Parse’s high‑throughput single‑cell technologies and Codebreaker’s variant engineering to measure variant effects at scale; the data are intended for drug discovery, AI model training, and translational research. Qiagen’s pending acquisition of Parse was noted in the coverage and may affect distribution and integration strategies. This collaboration targets a major bottleneck—linking genotype to cellular phenotype—and could accelerate functional interpretation of rare variants and validation of therapeutic targets when datasets reach sufficient scale and quality.